Laboratory Medicine Program

Acute Lymphocytic Leukemia: ABL1 Kinase Domain Mutation (p210, p190)

Clinical Decription:
Acute lymphocytic leukemia (ALL) patients harboring a fusion of the BCR and ABL1 genes are sensitive to treatment with tyrosine kinase inhibitors (TKI). Additional acquired mutations occurring in the Kinase Domain of ABL1 can antagonize the effects of TKI treatment. Sequencing of the Kinase Domain of ABL1 is performed to detect the TKI resistant mutations and determine optimal therapeutic avenues for ALL patients.

Method: PCR

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Peripheral Blood/Bone Marrow/Extracted RNA
Volume: n/a

Shipping: room temperature or 4C

Special Instructions: Test will be billed to the referring hospital, laboratory, physician or medical group. See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227